Home BancShares, Inc. (HOMB) Stock Price & Analysis
Home BancShares, Inc. (HOMB) closed at USD 30.15 on Thursday, October 22, 2026, up 2.66% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 29.37; the Oct 22, 2026 session ranged USD 29.48–30.23 on volume of 1,533,329 shares. Market capitalization is $6.03B, with a 52-week range of USD 25.5–31.7 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 10:38 UTC.
Also available as compact Markdown for AI agents: nexqual.com/HOMB.md
Key facts (HOMB)
- Last four reported quarters (through Jun 30, 2026): revenue $1.12B, net income $479M (42.7% margin) (SEC filings).
- Valuation: P/E 12.6x (avg 12.9x at the last 3 fiscal year-ends).
- 1 of 80 tracked superinvestors hold HOMB (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Insider open-market sales, last ~7 months: 4 Form 4 filings, $976K; 4 not under a Rule 10b5-1 plan ($976K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $2.7M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Hold (mean 2.50 on a 1–5 scale) (10 analysts), mean target USD 32.75 (range 31–35).
- Total return with dividends: 1Y +14.3% vs S&P 500 +14.9%; 5Y +42.1% vs S&P 500 +80.3%.
- Next earnings: 2027-01-13, EPS estimate USD 0.65, revenue estimate $293M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (HOMB)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $711M | $934M | $997M | $1.02B | $1.09B | $1.12B |
| Net income | $319M | $305M | $393M | $402M | $475M | $479M |
| EPS (diluted) | $1.94 | $1.57 | $1.94 | $2.01 | $2.41 | — |
| Free cash flow | $379M | $394M | $357M | $422M | $377M | $430M |
| Net margin | 44.9% | 32.7% | 39.4% | 39.5% | 43.6% | 42.7% |
| Revenue growth | +2.3% | +31.4% | +6.8% | +2.1% | +7.2% | — |
| Cash + short-term investments | $3.65B | $725M | $1.00B | $910M | $667M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (HOMB)
P/E 12.6x · P/S 5.4x · P/FCF 14.0x · P/B 1.3x · FCF yield 7.13% · Earnings yield 7.95% · Dividend yield (paid, TTM) 2.72% · Buyback yield (TTM) 1.32%
P/E at fiscal year-ends: Dec 2025 11.5x, Dec 2024 14.1x, Dec 2023 13.1x.
Superinvestors (SEC 13F-HR, Q2 2026) (HOMB)
1 of 80 tracked investors hold HOMB. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Bruce Berkowitz | Fairholme Capital | 0.02% | $345K | Unchanged |
Insider sales (SEC Form 4, open-market, last ~7 months) (HOMB)
0 of 4 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-11 | Rankin Jim | Director | 15,000 | $463K | 6.7% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-04 | Tipton John Stephen | Centennial Bank CEO | 12,000 | $379K | 10.3% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-01 | Allison John W Ii | Director | 2,000 | $53K | 0.3% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-04-21 | Floyd Jennifer C. | Chief Accounting Officer | 3,000 | $81K | 39.3% | No | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Insider purchases (SEC Form 4, open-market, last ~7 months) (HOMB)
1 purchase, $2.7M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-04-17 | Allison John W | Chairman & CEO | 100,000 | $2.7M | 26.96 | Too little history (no open-market trades in 2023) |
Analysts (HOMB)
Consensus Hold (mean 2.50 on a 1–5 scale), 10 analysts; mean target USD 32.75 (low 31, high 35).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | Citigroup | Target lowered | Neutral | $32 → $31 |
| 2026-10-16 | Piper Sandler | Target lowered | Overweight | $36 → $34 |
| 2026-09-08 | Hovde Group | Initiated | Outperform | $34 |
| 2026-08-19 | Cantor Fitzgerald | Target raised | Neutral | $30 → $31 |
| 2026-07-21 | Citigroup | Target raised | Neutral | $29 → $32 |
| 2026-07-17 | Piper Sandler | Target raised | Overweight | $33 → $36 |
| 2026-07-17 | Stephens & Co. | Target raised | Overweight | $32 → $35 |
| 2026-07-17 | Keefe, Bruyette & Woods | Target raised | Market Perform | $30 → $32 |
Total return (dividends reinvested) (HOMB)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +14.3% | +42.1% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +14.3% | +7.3% |
| Volatility (annualized) | 19.8% | 25.3% |
| Max drawdown | -14.8% (Feb 2026→May 2026) | -21.7% (Nov 2022→May 2023) |
HOMB revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Other service charges and fees | $13.0M | — | +2.6% |
| Service charges on deposit accounts | $10.0M | — | +5.0% |
| Total revenue | — | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
HOMB analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $0.65 | $0.64 | +1.7% | $292.5M | 10 |
| Next quarter (ends Mar 2027) | $0.62 | $0.62 | +0.8% | $288.0M | 9 |
| Current fiscal year (ends Dec 2026) | $2.53 | $2.52 | +0.7% | $1.15B | 10 |
| Next fiscal year (ends Dec 2027) | $2.60 | $2.59 | +0.5% | $1.18B | 10 |
Key Statistics (as of October 23, 2026 at 10:38 UTC)
| Price | USD 30.15 |
|---|---|
| Change | ▲ 2.66% (up) |
| Previous Close | USD 29.37 |
| Open | USD 29.53 |
| Day Range | USD 29.48 – 30.23 |
| 52-Week Range | USD 25.5 – 31.7 |
| Volume | 1,533,329 shares |
| Market Cap | $6.03B |
| Exchange | NYQ |
Technical Analysis (HOMB)
Nexqual's technical model rates HOMB "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 10:38 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 64.56 (neutral) |
| vs SMA50 | Above (USD 29.47) |
| MACD | 0.03 (positive) |
Analyst Ratings (HOMB)
Wall Street analysts rate HOMB "Hold" based on 10 analysts, with a mean price target of USD 32.75 (range USD 31–35), per Nexqual as of October 23, 2026 at 10:38 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 32.75 |
| High Target | USD 35 |
| Low Target | USD 31 |
| Buy / Hold / Sell | 4 / 6 / 0 |
Earnings (HOMB)
| Next Earnings Date | 2027-01-13 |
|---|---|
| EPS Estimate | USD 0.65 |
| Revenue Estimate | $292.52M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD 0.65 vs est 0.64 ▲ beat |
| 2026-06-30 | USD 0.64 vs est 0.61 ▲ beat |
| 2026-03-31 | USD 0.6 vs est 0.59 ▲ beat |
| 2025-12-31 | USD 0.6 vs est 0.6 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
Financials & Fundamentals (HOMB)
| Total Revenue | $1.12B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +5.80% |
| Gross Margin | +0.00% |
| Operating Margin | +57.79% |
| Profit Margin | +43.51% |
| ROE | +11.10% |
| Total Cash | $863.08M |
| Total Debt | $691.20M |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
Financial Health Score (HOMB)
Nexqual rates Home BancShares, Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 10:38 UTC.
| Growth | Solid — Revenue +7% YoY (annual) |
|---|---|
| Profitability | Strong — Net margin 43% (last 12 months); banks have no gross margin |
| Balance Sheet | N/A — Not comparable for banks: deposits and customer funds sit on the balance sheet, so cash vs debt does not measure safety (SEC industry: State Commercial Banks) |
| Cash Flow | N/A — Not meaningful for banks and lenders: lending and trading move operating cash flow by billions each year (SEC industry: State Commercial Banks) |
| Efficiency | Mixed — ROE 11%, ROA 2.1% |
Ownership (HOMB)
| Insider Ownership | +6.37% |
|---|---|
| Institutional Ownership | +79.47% |
| Shares Outstanding | 200.05M |
| Float | 186.70M |
| Short % of Float | +6.91% |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
Leadership (HOMB)
Home BancShares, Inc. is led by John W. Allison, Co-Founder, Chairman & CEO, per Nexqual as of October 23, 2026 at 10:38 UTC.
| Co-Founder, Chairman & CEO | John W. Allison |
|---|---|
| President & Chief Lending Officer | Kevin D. Hester |
| CFO, Treasurer & Director | Brian S. Davis |
| Chief Operating Officer | John Stephen Tipton |
| Senior EVP, Director of Investor Relations, Corporate Secretary & Director | Donna J. Townsell |
Major Backers & Investors (HOMB)
Notable institutional backers of Home BancShares, Inc. include T. Rowe Price, Capital Group, SmallCap World Fund Inc, according to Nexqual as of October 23, 2026 at 10:38 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 4.31% |
| Capital Group | 2.57% |
| SmallCap World Fund Inc | 2.5% |
| AQR Capital Management, LLC | 2.41% |
| American Century Companies Inc | 2.23% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 12.88% |
| Vanguard Group | 10.27% |
| State Street | 5.01% |
| Dimensional Fund Advisors | 3.61% |
| Geode Capital | 2.53% |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
From Home BancShares, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- We have a centralized loan review process, which we believe enables us to take prompt action on potential problem loans.
Partnerships
- Centennial Bank also contracts with Ameriprise Financial Services, LLC ("Ameriprise"), a registered broker-dealer and investment adviser, to offer and sell various securities and other financial products to customers through associates who are employed by both Centennial Bank and Ameriprise.
- The regional Officers' Loan Committees have approval authority of up to $2.0 million aggregate debt on all new secured loans, $2.0 million individual loan amount on all secured renewals, $100,000 aggregate debt on all unsecured new loans and $100,000 individual loan amount on all unsecured renewals.
Legal & Regulatory Risks (Item 1A, quoted)
- Our operations could be interrupted if certain external vendors on which we rely experience difficulty, terminate their services or fail to comply with banking laws and regulations.
- Our earnings could be adversely impacted by incidences of fraud and compliance failure.
- We may not have sufficient earnings since our primary source of income, the payment of dividends to us by our bank subsidiary, is subject to federal and state laws that limit the ability of that bank to pay dividends.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BBD | Banco Bradesco Sa | USD 3.95 | ▼ 2.47% |
| FITB | Fifth Third Bancorp | USD 53.23 | ▲ 0.8% |
| TFC | Truist Financial Corporation | USD 48.42 | ▲ 1.45% |
| DB | Deutsche Bank AG | USD 31.48 | ▼ 2.39% |
| NWG | NatWest Group plc | USD 16.99 | ▼ 2.3% |
| NU | Nu Holdings Ltd. | USD 14.73 | ▼ 2.13% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:38 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt